Taletrectinib
Taletrectinib (AB-106) is a next-generation, selective ROS1/NTRK inhibitor with potent activity against ROS1, NTRK1, NTRK2, and NTRK3. It has demonstrated promising antitumor efficacy in both in vitro and in vivo models, supporting its ongoing clinical research in oncology for cancers driven by these kinase fusions.
Product Specifications
CAS Number
1505515-69-4
Product Name Alternative
Colorectal, DS-6051b, AB106, AB-106, AB 106, cancer, antitumor, NSCLC, inhibit, mutations, Inhibitor, glioblastoma, rearrangement, Taletrectinib, Trk receptor, TrkA, TrkB, TrkC, Trkreceptor, ROS Kinase, ROSKinase, ROS1, ROS
Field of Research
Immunology & Inflammation, Signal Transduction
Purity
99.87% (May vary between batches)
Solubility
10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (3.63 mM) ; DMSO:45 mg/mL (81.58 mM)
Smiles
OC (=O) CCCCC (O) =O.C[C@@H] (N) COc1ccc (cc1) -c1cnc2ccc (N[C@H] (C) c3cccc (F) c3) nn12
Molecular Formula
C29H34FN5O5
Molecular Weight
551.61
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
More Discoveries
Explore Other Products
Browse additional items from our catalog
